Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Atairgin, Northwestern U. develop cancer diagnostics

Executive Summary

Northwestern University will use Atairgin Technologies' (reproductive cancer diagnostics and therapeutics) lysophospholipid platform technology to develop for the company an early detection marker for ovarian cancer. Dr. David Fishman, the director of NU's ovarian cancer detection program whose expertise is in bioactive lipids, will carry out the research.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies